Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.42 |
| ▸ | PDE8B | O95263 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 2/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL894504 | 1.00 | HSD17B10 (0.50) | HSD17B10SMN1; SMN2ALDH1A1FFAR1PDE8B | |
| SCHEMBL144831 | 1.00 | HSD17B10 (0.50) | HSD17B10SMN1; SMN2ALDH1A1FFAR1PDE8B | |
| Hydrochloric Acid SCHEMBL25198974 | 0.98 | HSD17B10 (0.49) | HSD17B10SMN1; SMN2ALDH1A1FFAR1PDE8B | |
| SCHEMBL5781434 | 0.95 | HSD17B10 (0.46) | HSD17B10SMN1; SMN2ALDH1A1FFAR1PDE8B | |
| SCHEMBL1255187 | 0.95 | HSD17B10 (0.46) | HSD17B10SMN1; SMN2ALDH1A1FFAR1PDE8B | |
| SCHEMBL79878 | 0.95 | HSD17B10 (0.46) | HSD17B10SMN1; SMN2ALDH1A1FFAR1PDE8B | |
| SCHEMBL17395340 | 0.94 | PDE8B (0.45) | HSD17B10SMN1; SMN2ALDH1A1PDE8BATM | |
| SCHEMBL5192786 | 0.94 | PDE8B (0.45) | HSD17B10SMN1; SMN2ALDH1A1PDE8BATM | |
| SCHEMBL25415724 | 0.92 | HSD17B10 (0.56) | HSD17B10SMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL2462455 | 0.90 | HSD17B10 (0.43) | HSD17B10SMN1; SMN2ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 220 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037329-B2 | SphK inhibitors and methods of making and using same | WASHINGTON UNIVERSITY (US) | 2024-07-16 | — | — | US | claimed |
| CN-116874803-A | Antibacterial dendritic polyester polymer and preparation method and application thereof | 清华大学深圳国际研究生院 | 2023-10-13 | — | — | CN | claimed |
| US-20230150990-A1 | SPHK INHIBITORS AND METHODS OF MAKING AND USING SAME | WASHINGTON UNIVERSITY | 2023-05-18 | — | — | US | claimed |
| WO-2026085629-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2026-04-30 | — | — | WO | disclosed |
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | PEPTIDREAM INC (JP) | 2026-01-15 | — | — | US | disclosed |
| US-12492200-B2 | NLRP3 modulators | Birstol Myers-Squibb Company (US) | 2025-12-09 | — | — | US | disclosed |
| US-20250281424-A1 | SMALL MOLECULE ANTAGONISTS OF PF4 | ZHOU YUHANG (US) | 2025-09-11 | — | — | US | disclosed |
| US-20250206724-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2025-06-26 | — | — | US | disclosed |
| US-12303544-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | ZYMEWORKS BC INC. (CA) | 2025-05-20 | — | — | US | disclosed |
| CN-115380030-B | N-heteroarylalkyl-2- (heterocyclyl and heterocyclylmethyl) acetamide derivatives as SSTR4 agonists | 武田药品工业株式会社 | 2025-05-16 | — | — | CN | disclosed |
| WO-2025090774-A1 | CHEMOTHERAPEUTIC COMPOUNDS AND METHODS OF USE | SEAGEN INC. (US) | 2025-05-01 | — | — | WO | disclosed |
| EP-1406897-A2 | COMPOUNDS | SmithKline Beecham plc (GB) | 2004-04-14 | — | — | EP | disclosed |
| EP-1399441-A1 | N-AROYL CYCLIC AMINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2004-03-24 | — | — | EP | disclosed |
| WO-2003076440-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS CALCITONIN AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-09-18 | — | — | WO | disclosed |
| WO-2003002559-A2 | PIPERIDINE COMPOUNDS FOR USE AS OREXIN RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-01-09 | — | — | WO | disclosed |
| WO-2003002561-A1 | N-AROYL CYCLIC AMINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-01-09 | — | — | WO | disclosed |
| EP-0491943-A4 | TETRAHYDROPYRIDOINDOLES AS CHOLECYSTOKININ AND GASTRIN ANTAGONISTS | RORER INT HOLDINGS (US) | 1996-02-14 | — | — | EP | disclosed |
| EP-0491943-A1 | TETRAHYDROPYRIDOINDOLES AS CHOLECYSTOKININ AND GASTRIN ANTAGONISTS | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1992-07-01 | — | — | EP | disclosed |
| WO-1992000295-A1 | TETRAHYDROPYRIDOINDOLES AS CHOLECYSTOKININ AND GASTRIN ANTAGONISTS | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1992-01-09 | — | — | WO | disclosed |
| US-4634716-A | ANGIOTENSIN CONVERTING ENZYME INHIBITORS | MERCK & CO., INC. (US) | 1987-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037329-B2 | SphK inhibitors and methods of making and using same | SPHK2, SPHK1, CLK2 | HSD17B10 1749/4885SMN1; SMN2 3760/4885ALDH1A1 4057/4885 |
| US-12492200-B2 | NLRP3 modulators | NLRP3, NLRP1, PYCARD | HSD17B10 1231/4885SMN1; SMN2 4769/4885ALDH1A1 864/4885 |
| US-20250206724-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | CDK1, CDK11A, CDK3 | HSD17B10 3713/4885SMN1; SMN2 2939/4885ALDH1A1 4385/4885 |
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | NSUN3, BCAT1, SLC43A1 | HSD17B10 1075/4885SMN1; SMN2 1555/4885ALDH1A1 2330/4885 |
| US-20250281424-A1 | SMALL MOLECULE ANTAGONISTS OF PF4 | PF4, F12, F2 | HSD17B10 1989/4885SMN1; SMN2 4700/4885ALDH1A1 4728/4885 |
| US-12303544-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | CCNB1, PLK1, BOD1L1 | HSD17B10 3340/4885SMN1; SMN2 860/4885ALDH1A1 3393/4885 |
| US-20230150990-A1 | SPHK INHIBITORS AND METHODS OF MAKING AND USING SAME | SPHK2, SPHK1, CLK2 | HSD17B10 1749/4885SMN1; SMN2 3760/4885ALDH1A1 4057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.